Although these findings consolidated the notion of therapeutic modulation of LKB1/AMPK/mTOR signaling as a valuable strategy for preventing cardiac hypertrophy and HF, effective pharmacological treatments aimed at this end remain to be developed. This evidence concerns the gene MTOR and cardiac hypertrophy.